KLRK1 and melanoma: The study of the NK cell phenotype in these advanced melanoma patients revealed that the levels of NKG2D were profoundly decreased compared with normal volunteers prior to Dex vaccination (Fig. 5C) (36±22%) but significantly rose (p = 0.011) after 4 injections of Dex vaccines to 61±28% (Fig. 5C).